Market Closed -
Nasdaq
16:30:00 2024-05-06 EDT
|
5-day change
|
1st Jan Change
|
1.84
USD
|
0.00%
|
|
+9.52%
|
-8.46%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
150
|
1,081
|
255.9
|
284.9
|
260.9
|
-
|
-
|
Enterprise Value (EV)
1 |
150
|
1,081
|
255.9
|
284.9
|
260.9
|
260.9
|
260.9
|
P/E ratio
|
-1.86
x
|
-6.61
x
|
-1.93
x
|
-2.96
x
|
-2.26
x
|
-2.24
x
|
-2.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
263
x
|
64
x
|
20.5
x
|
8.54
x
|
EV / Revenue
|
-
|
-
|
-
|
263
x
|
64
x
|
20.5
x
|
8.54
x
|
EV / EBITDA
|
-
|
-16.9
x
|
-2.54
x
|
-3.02
x
|
-2.75
x
|
-2.54
x
|
-2.52
x
|
EV / FCF
|
-
|
-14.9
x
|
-2.53
x
|
-2.89
x
|
-2.64
x
|
-3.11
x
|
-3
x
|
FCF Yield
|
-
|
-6.71%
|
-39.6%
|
-34.6%
|
-37.9%
|
-32.1%
|
-33.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,780
|
137,416
|
139,819
|
141,728
|
141,816
|
-
|
-
|
Reference price
2 |
10.15
|
7.870
|
1.830
|
2.010
|
1.840
|
1.840
|
1.840
|
Announcement Date
|
21-04-07
|
22-02-28
|
23-03-06
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1.082
|
4.076
|
12.71
|
30.57
|
EBITDA
1 |
-
|
-64.03
|
-100.6
|
-94.26
|
-95
|
-102.9
|
-103.4
|
EBIT
1 |
-
|
-96.91
|
-123.8
|
-111.2
|
-107.2
|
-110.7
|
-110.6
|
Operating Margin
|
-
|
-
|
-
|
-10,274.58%
|
-2,629.92%
|
-870.9%
|
-361.7%
|
Earnings before Tax (EBT)
1 |
-
|
-94.99
|
-132.4
|
-95.96
|
-107.2
|
-110.7
|
-110.6
|
Net income
1 |
-36.61
|
-94.99
|
-132.4
|
-95.96
|
-107.2
|
-110.7
|
-110.6
|
Net margin
|
-
|
-
|
-
|
-8,868.76%
|
-2,629.92%
|
-870.9%
|
-361.7%
|
EPS
2 |
-5.450
|
-1.190
|
-0.9500
|
-0.6800
|
-0.8150
|
-0.8200
|
-0.7650
|
Free Cash Flow
1 |
-
|
-72.58
|
-101.3
|
-98.55
|
-99
|
-83.8
|
-87
|
FCF margin
|
-
|
-
|
-
|
-9,107.76%
|
-2,428.85%
|
-659.53%
|
-284.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-04-07
|
22-02-28
|
23-03-06
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.254
|
0.205
|
0.223
|
0.4
|
0.4265
|
0.677
|
1.168
|
1.805
|
2.4
|
EBITDA
1 |
-17.52
|
-20.38
|
-27.4
|
-25.82
|
-22.89
|
-24.46
|
-23.7
|
-22.87
|
-22.61
|
-25.08
|
-23.3
|
-23.7
|
-24
|
-24
|
-24.1
|
EBIT
1 |
-25.18
|
-27.79
|
-27.14
|
-30.2
|
-27.66
|
-38.84
|
-29.22
|
-26.89
|
-27.18
|
-27.88
|
-26.97
|
-26.93
|
-26.79
|
-26.45
|
-27.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,504.33%
|
-13,118.05%
|
-12,186.1%
|
-6,970.75%
|
-6,323.45%
|
-3,977.92%
|
-2,294.9%
|
-1,465.51%
|
-1,158.33%
|
Earnings before Tax (EBT)
1 |
-18.09
|
-29.42
|
-35.18
|
-32.41
|
-31.71
|
-33.14
|
-23.61
|
-25.57
|
-24.73
|
-22.05
|
-26.97
|
-26.93
|
-26.79
|
-26.45
|
-27.8
|
Net income
1 |
-18.09
|
-29.42
|
-35.18
|
-32.41
|
-31.71
|
-33.14
|
-23.61
|
-25.57
|
-24.73
|
-22.05
|
-26.97
|
-26.93
|
-26.79
|
-26.45
|
-27.8
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-9,295.67%
|
-12,474.63%
|
-11,088.79%
|
-5,512%
|
-6,323.45%
|
-3,977.92%
|
-2,294.9%
|
-1,465.51%
|
-1,158.33%
|
EPS
2 |
-0.1300
|
-0.2100
|
-0.2500
|
-0.2300
|
-0.2300
|
-0.2400
|
-0.1700
|
-0.1800
|
-0.1700
|
-0.1600
|
-0.2100
|
-0.2050
|
-0.2050
|
-0.2000
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-10
|
22-02-28
|
22-05-09
|
22-08-08
|
22-11-07
|
23-03-06
|
23-05-11
|
23-08-07
|
23-11-09
|
24-02-29
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-72.6
|
-101
|
-98.5
|
-99
|
-83.8
|
-87
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
5.76
|
10.7
|
4.51
|
7.5
|
11.5
|
15
|
Capex / Sales
|
-
|
-
|
-
|
416.82%
|
184%
|
90.51%
|
49.07%
|
Announcement Date
|
21-04-07
|
22-02-28
|
23-03-06
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
1.84
USD Average target price
2.72
USD Spread / Average Target +47.83% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.46% | 261M | | +22.81% | 46.81B | | +46.56% | 41.29B | | -1.88% | 41.37B | | -6.20% | 28.87B | | +11.33% | 26.06B | | -21.00% | 19.13B | | -1.43% | 11.96B | | +30.73% | 12.39B | | -0.48% | 12.08B |
Other Biotechnology & Medical Research
|